Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.
about
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allPharmacogenetics as a tool to tailor antiretroviral therapy: A reviewInfluence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patientsPHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG).The effect of retrospective sampling on estimates of prediction error for multifactor dimensionality reduction.T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384.Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic successStatistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to AnalysisPopulation pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients.Individualization of antiretroviral therapy."One pill, once daily": what clinicians need to know about Atriplatrade mark.Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.Advances in pharmacogenomics of antiretrovirals: an update.Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyEFV/FTC/TDF-associated hepatotoxicity: a case report and review.Genomic convergence to identify candidate genes for Alzheimer disease on chromosome 10.Pharmacogenomics of CYP3A: considerations for HIV treatment.Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapineMethodological and statistical issues in pharmacogenomics.Pharmacogenetics of antiretroviral therapy.Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.Impact of pharmacogenetics on CNS side effects related to efavirenz.Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review.Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
P2860
Q24609011-1DF6D7A2-66E5-4892-98E9-70489B9AE414Q26797938-FB6D2574-ED12-4EF9-8ABD-EE74893CE463Q28293875-E302F414-E1D0-4AD2-BB87-26C72997C439Q31037300-FB2B9566-7519-4BA7-A0FD-C00A902061F6Q34203716-0BBBE9DB-4B1E-43E0-AAC1-75C51AB279A3Q34411977-AEF849C5-88A4-4761-B1F5-846A6BD67364Q34443184-F08A13F9-5ECB-4B48-8106-D0AD0B9CAB92Q35043700-F4A2F5FD-E595-4921-918F-4E3EE1F8089FQ35185164-0C62345A-3C50-46A6-A0A2-4710F39DA81FQ35364120-C5B92362-61FA-4A72-95B3-19BB71036F27Q35476308-028DC76E-64A8-4DE1-A014-C5C03539BCE6Q36079108-EE353317-F6A4-46B4-8446-1796F8EE5918Q36370484-38E6EC10-277F-4F94-8F71-5D08AB471688Q36441423-EE60EFF7-75AF-46A9-ACE9-0CDCFE41B552Q36823570-4D9DF4E4-E230-468C-80CA-A323FC4E2F4BQ36885659-FD8E9654-41C1-4CA0-8C42-F69A34B6C300Q36966025-A7F41988-1875-4657-962B-06666CDF8F34Q37026878-823ABE51-AB44-41BC-B3B5-CBD6E095D61CQ37139458-D9D83856-93FE-4C0F-AFF1-1B7DFAE932E8Q37270145-E495C15E-C48B-478E-BD12-F26B06E67D2FQ37419542-DCAE9B83-53C0-472B-98C4-DE0BEC14F379Q37613197-8650077E-B19E-4508-A274-A6DC5BEB8DF2Q37757136-D34CDA66-1533-4DEF-AD5A-CAADF342894AQ38221179-8BA20E16-8A8F-43A6-848B-8ED0FC78A4EAQ38957969-33985E3D-0879-4E2B-8FAC-D2C64D3DC77DQ39383647-C762F640-C51D-4E96-AF0B-F1ACEB7D389BQ52330065-14050230-290C-4A94-8F7E-C575F844BA24Q53547764-21BC33B4-0C43-4608-9077-002ED5861CE1
P2860
Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Multilocus genetic interaction ...... S clinical trials group study.
@ast
Multilocus genetic interaction ...... S clinical trials group study.
@en
Multilocus genetic interaction ...... S clinical trials group study.
@nl
type
label
Multilocus genetic interaction ...... S clinical trials group study.
@ast
Multilocus genetic interaction ...... S clinical trials group study.
@en
Multilocus genetic interaction ...... S clinical trials group study.
@nl
prefLabel
Multilocus genetic interaction ...... S clinical trials group study.
@ast
Multilocus genetic interaction ...... S clinical trials group study.
@en
Multilocus genetic interaction ...... S clinical trials group study.
@nl
P2093
P1476
Multilocus genetic interaction ...... S clinical trials group study.
@en
P2093
Alison A Motsinger
David B Clifford
David W Haas
Gene D Morse
Grant R Wilkinson
Gregory K Robbins
John P Donahue
Line Labbe
Martin S Hirsch
Richard B Kim
P304
P356
10.1097/01.FPC.0000230413.97596.FA
P577
2006-11-01T00:00:00Z